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OBJECTIVE—To compare in the Swiss population the results of several scores estimating the
risk of developing type 2 diabetes.
RESEARCHDESIGNANDMETHODS—This was a single-center, cross-sectional study
conducted between 2003 and 2006 in Lausanne, Switzerland. Overall, 3,251 women and 2,937
men, aged 35–75 years, were assessed, of which 5,760 (93%) were free from diabetes and in-
cluded in the current study. The risk of developing type 2 diabetes was assessed using seven
different risk scores, including clinical data with or without biological data. Participants were
considered to be eligible for primary prevention according to the thresholds provided for each
score. The results were then extrapolated to the Swiss population of the same sex and age.
RESULTS—The risk of developing type 2 diabetes increased with age in all scores. The prev-
alence of participants at high risk ranged between 1.6 and 24.9% in men and between 1.1 and
15.7% in women. Extrapolated to the Swiss population of similar age, the overall number of
participants at risk, and thus susceptible to intervention, ranged between 46,708 and 636,841. In
addition, scores that included the same clinical variables led to a signiﬁcantly different prevalence
of participants at risk (4.2% [95% CI 3.4–5.0] vs. 12.8% [11.5–14.1] in men and 2.9% [2.4–3.6]
vs. 6.0% [5.2–6.9] in women).
CONCLUSIONS—The prevalence of participants at risk for developing type 2 diabetes varies
considerably according to the scoring system used. To adequately prevent type 2 diabetes, risk-
scoring systems must be validated for each population considered.
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Type 2 diabetes is a serious diseasewith increasing prevalence. This dis-ease remains asymptomatic for years,
being discovered only at a stage with
preexisting complications (1). Recent stud-
ies (2) have shown that lifestyle or medi-
cation intervention could prevent the
incidence of type 2 diabetes. Hence, screen-
ing tools are needed to identify participants
with undiagnosed diabetes or those who
are at risk for developing diabetes in
the future. For this purpose, numerous
risk scores recently have been proposed
(3–6). Participants at high risk of devel-
oping type 2 diabetes, according to the
risk score threshold, are thus amenable
to preventive measures. A good diabetes
risk score ideally should be easily com-
pleted by the physician and rely on easily
and routinely accessible clinical and bio-
logical parameters, such as age, family his-
tory, hypertension, anthropometry, or
lifestyle habits. Moreover, the risk score
has to be accurate enough to provide tar-
geted warnings for the patients. Some
scores have been validated in selected
populations (3–7), prompting their use in
other countries (8,9). Nevertheless, recent
studies (10) have shown that risk scores
that are developed in the same country
can lead to different results. Likewise, one
equation validated in one country might
not provide adequate estimates in another;
for instance, the Framingham cardiovascu-
lar risk equations can over- or underesti-
mate risk when directly applied to other
populations (11). Finally, and to the best
of our knowledge, no study has ever com-
pared the results of differing scoring sys-
tems in Switzerland.
The current study aimed to compare
the results of several scores that estimate
the risk of developing type 2 diabetes
using data from the Cohorte Lausannoise
(CoLaus) study, a cross-sectional study
conducted in Lausanne, Switzerland. The
resulting number of subjects at risk for
developing type 2 diabetes in Switzerland
according to these different risk equations
also was estimated.
RESEARCH DESIGN AND
METHODS
Risk scores
We performed a PubMed search and
selected risk scores for their relative nov-
elty and their applicability to the Swiss
population. The score from the Swiss
Diabetes Association, available on the
Internet (8), also was assessed. This score
actually is an adaptation of the Finnish
Diabetes Risk Score (FINDRISC) score
(7). Overall, seven risk scores, including
clinical (C) or clinical and biological var-
iables (CB) were studied: 10-year risk
scores from Kahn et al. (3) (C and CB);
8-year risk score from Wilson et al. (4)
(CB); 9-year risk score from Balkau et al.
(6) (C); the prevalent undiagnosed diabe-
tes risk score fromGrifﬁn et al. (5) (C); the
risk score from the Swiss Diabetes Asso-
ciation (8); and the FINDRISC (C), which
is a 5- to 10-year risk score (7). The char-
acteristics of the studies, where the scores
were developed, and the variables in-
cluded in each score are summarized in
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Supplementary Tables 1 and 2. From this
point on, the scores will be referenced by
the name of the ﬁrst author, with a further
differentiation by C or CB in the case of
the Kahn and Balkau scores.
We used the thresholds recommended
by the authors to deﬁne participants at
high risk of developing type 2 diabetes
(Supplementary Table 1). These thresh-
olds were deﬁned differently according
to the study: Kahn (3), Wilson (4), and
Balkau (6) used a probability, whereas the
Swiss Diabetes Association and FINDRISC
used a score above a given number of
points. The initial publication fromGrifﬁn
et al. (5) provided no threshold; hence, we
used the 37% probability, which was used
in another study (12). The scores from the
Swiss Diabetes Association and FINDRISC
included regular consumption of selected
foods (fruits, vegetables, berries, and
brown bread) and familial history of dia-
betes for second-degree parents (grand-
parents, cousins, and uncles). Because
these data were not available in our study,
the scoring system was adapted by reduc-
ing by one point the cutoff value for high-
risk participants.
Recruitment
The CoLaus study is a cross-sectional study
in the Caucasian population of Lausanne,
Switzerland, a town of 117,161 inhab-
itants, of which 79,420 are of a Swiss
nationality. This study was approved by
the institutional ethics committee of the
University of Lausanne. The study was de-
signed to assess the prevalence and to
identify the molecular determinants of
cardiovascular risk factors. The population
of Lausanne can be considered as repre-
sentative of the whole country because a
considerable proportion is non-Swiss or
comes from other cantons (political re-
gions of Switzerland). In 2006, of 128,231
Lausanne inhabitants, 38%were non-Swiss,
30% came from other cantons (including
Italian andGerman-speaking cantons), and
only 32% were actually from the Vaud
canton (13).
The sampling procedure of the
CoLaus study has been described previ-
ously (14). A complete list of Lausanne in-
habitants, aged 35–75 years (n = 56,694),
was provided by the population registry of
the city. A simple, nonstratiﬁed random
sample of 35% of the overall population
was drawn. The following inclusion criteria
were applied: 1) providedwritten informed
consent; 2) was aged 35–75 years; 3) was
willing to take part in the examination
and donate blood samples; and 4) was of
Caucasian origin, deﬁned as having both
parents and grandparents born in a re-
stricted list of countries (available from
the authors). Recruitment began in June
2003 and ended inMay 2006. Participation
rate was 41%, and 6,188 Caucasian partic-
ipants (3,251women and 2,937men) took
part in the study.
All participants attended the outpa-
tient clinic of the University Hospital of
Lausanne in the morning after an over-
night fast (minimum fasting time 8 h).
Data were collected by trained ﬁeld inter-
viewers in a single visit lasting ~60 min.
Clinical data
The participants ﬁrst received a question-
naire to record information about their
lifestyle factors, namely tobacco use, al-
cohol use, and physical activity. According
to their smoking histories, participants
were classiﬁed as never, current, or former
smokers. Current smokers were deﬁned as
giving a positive answer to the statement
“I currently smoke,” former smokers were
deﬁned as giving a positive answer to the
statement “I don’t smoke anymore,” and
never smokers were deﬁned as giving a
positive answer to the statement “I have
never smoked.” Alcohol consumption in-
cluded past and current drinking status as
well as the number of alcoholic beverage
units (wine, beer, and spirits) consumed
over the week preceding the interview. A
participant was considered to be physi-
cally active if he/she reported practicing
at least 2 h of leisure-time physical activity
per week.
During a second face-to-face meeting,
the participants were asked if they or their
ﬁrst-degree family (i.e., parents, children)
had presented with diabetes. The partic-
ipants also were asked if they had been
diagnosed with hypertension or if they
currently were being treated for hyper-
tension. Personal medicines, including
prescription and self-prescribed drugs,
were collected, together with their main
indications. Only corticosteroids, being
of systemic or topical use, were consid-
ered for testing the scores. Despite the fact
that other medications, such as hydrochlo-
rothiazide or ACE inhibitors, have been
shown to inﬂuence diabetes status (15),
they were not included in the risk scores.
Body weight and height were mea-
sured with participants standing without
shoes in light indoor clothes. Body weight
was measured in kilograms to the nearest
100 g, using a Seca scale, which was
calibrated regularly. Height was mea-
sured to the nearest 5 mm using a Seca
height gauge. Waist was measured with a
nonstretchable tape over the unclothed
abdomen at the narrowest point between
the lowest rib and the iliac crest. Two
measures were made, and the mean (ex-
pressed in centimeters) was used for
analyses. Blood pressure and resting pulse
were measured three times using an
Omron HEM-907 automated oscillomet-
ric sphygmomanometer on the left arm,
with an appropriately sized cuff, after at
least 10 min rest in the seated position.
The average of the last two measurements
was used for analyses.
Biological analyses
Fasting plasma glucose, HDL cholesterol,
LDL cholesterol, triglycerides, and uric
acid levels were measured by the Centre
Hospitalier Universitaire Vaudois Clinical
Laboratory using fresh blood samples
within 2 h of blood collection. All meas-
urements were conducted in a Modular P
apparatus (Roche Diagnostics, Basel,
Switzerland). The following analytical pro-
cedures (with maximum interbatch and
intrabatch coefﬁcients of variation) were
used: cholesterol by cholesterol oxidase-
peroxide + 4-aminophenazone + phenol
(PAP) (1.6–1.7%); HDL cholesterol by
cholesterol oxidase-PAP plus polyethylene-
glycol plus cyclodextrin (3.6–0.9%); glucose
by glucose dehydrogenase (2.1–1.0%);
triglycerides by glucose oxidase-PAP
(2.9–1.5%); and uric acid by uricase-PAP
(1.0–0.5%).
Diabetes
Diabetes was deﬁned as fasting plasma
glucose $7.0 mmol/L and/or the pres-
ence of oral hypoglycemic or insulin treat-
ment. Type 2 diabetes was deﬁned in
cases of diabetes without self-reported
type 1 diabetes. Impaired fasting glucose
was deﬁned as fasting plasma glucose be-
tween 6.1 and 6.9 mmol/L without anti-
diabetes treatment.
Statistical analysis
Of the initial 6,188 participants, 21
(0.3%) had missing data for the vari-
ables of interest, 407 (6.6%) had diabetes,
and 655 had impaired fasting glucose
(10.6%). Diabetic participants were ex-
cluded, and the remaining 5,760 (93.1%)
participants were used in the analyses.
Characteristics of the patients included in
our study are available in Supplementary
Table 1.
The prevalence of participants at risk
for developing type 2 diabetes according to
each score was determined and expressed
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in percentages and 95% CIs. The number
of participants at risk in Switzerland was
then estimated for each score by applying
the sex-speciﬁc and 10-year age-group–
speciﬁc prevalence obtained to the cor-
responding diabetes-free population
numbers, obtained by averaging the pop-
ulation estimates between 2003 and 2006,
provided by the Swiss Federal Statistical
Ofﬁce (www.statistique.admin.ch). To as-
sess the number of subjects without dia-
betes in the Swiss population, we assumed
that the proportion of nondiabetic pa-
tients in our study was representative of
the whole country. All statistical analyses
were made using Stata version 11.1 (Stata,
College Station, TX).
RESULTS
Prevalence of subjects at risk
for type 2 diabetes
The prevalence of participants at risk for
developing type 2 diabetes is shown in
Fig. 1. In men, the prevalence of partici-
pants at high risk of developing type 2
diabetes was the following: 1.6% (1.2–
2.2) (Wilson); 4.2% (3.4–5.0) (Balkau);
12.8% (11.5–14.1) (Kahn [C]); 13.5%
(12.2–14.9) (Swiss Diabetes Association);
13.7% (12.4–15.0) (Kahn [CB]); 22.9%
(21.3–24.5) (FINDRISC); and 24.9%
(23.4–26.6) (Grifﬁn). In women, the cor-
responding values were 1.1% (0.8–1.6)
(Wilson); 2.9% (2.4–3.6) (Balkau); 6.0%
(5.2–6.9) (Kahn [C]); 11.1% (10.0–12.3)
(Swiss Diabetes Association); 6.1% (5.3–
7.0) (Kahn [CB]); 15.7% (14.5–17.1)
(FINDRISC); and 10.7% (9.6–11.8)
(Grifﬁn). Overall, men tended to present
a higher risk of type 2 diabetes than
women. Extrapolated to the Swiss popula-
tion of the same age, the number of subjects
at risk ranged from 46,708 to 636,841,
more than a 13-fold variation (Table 1).
Restricting the analysis to participants
aged ,65 years showed either slight in-
creases (Wilson) or decreases (FINDRISC;
Grifﬁn) in the prevalence of subjects at risk
for developing type 2 diabetes (Supple-
mentary Table 4). Likewise, excluding
from the analysis the 11womenwith a pos-
sible pregnancy at examination did not
change the results (data not shown).
Comparison between scores
We also checked whether the same par-
ticipants were considered to be at risk
according to the different scores. For this,
we compared the participants at risk for
type 2 diabetes according to the scores
that led to the lowest prevalence (Wilson
and Balkau) and also according to the
scores that included the same clinical
variables (Balkau and Kahn [C]). The
results are presented in Fig. 2. The scores
classiﬁed a total of 612 participants as
being at risk: n = 78, Wilson; n = 201,
Balkau; and n = 558, Kahn (C). Of 78
participants at risk according to Wilson
et al. (4), only 21 (26.9%) also were con-
sidered at risk according to Balkau.
Likewise, of 201 participants at risk ac-
cording to Balkau, only 145 (72%) also
were considered at risk according to
Kahn (C). Only 19 patients were simulta-
neously classiﬁed as high-risk by all three
scores.
CONCLUSIONS—To our knowledge,
this is one of the few studies that assessed
the effect of differing type 2 diabetes risk–
scoring systems in a given population. In
agreement with previous studies (10,16),
our results indicate that the prevalence of
subjects at risk for developing type 2 di-
abetes varies considerably according to
the scoring system used. This has a con-
siderable impact in the number of sub-
jects susceptible of beneﬁting from
measures regarding the primary preven-
tion of type 2 diabetes.
The risk-scoring systems compared
in this study shared several types of
variables (Supplementary Table 1). For
instance, all of them included a genetic
background (personal or family history),
which can be explained by the association
between certain genes and diabetes (17),
and most of them also included age,
which has been shown to be related to
the risk of diabetes. Most scores also in-
cluded obesity markers, such as BMI or
waist circumference, as well as cardiovas-
cular risk factors, such as hypertension
and dyslipidemia, all of which are in-
volved in the metabolic syndrome deﬁni-
tion (18). Finally, some scores included
lifestyle habits, whether protective, such
as alcohol consumption and physical ac-
tivity, or deleterious, such as smoking,
also in agreement with previous ﬁndings
(19). It should be noticed that in some
studies nondrinkers and former drinkers
were included in the same group (3) and
that the nonlinear, U-shaped association
between alcohol consumption and the
risk of developing type 2 diabetes (20)
was not considered. Overall, these ﬁnd-
ings suggest that any generic scoring sys-
tem that included clinical variables known
to be related to type 2 diabetes (age, obe-
sity, cardiovascular risk factors, and life-
style) could be used to derive diabetes
risk scores but that the relative weight of
each variable might be different according
to the population considered. For in-
stance, age, obesity, and the other factors
mentioned vary by country, and this may
result in a differential importance to pre-
dict diabetes. Finally, the inclusion of
other variables, such as biological and ge-
netic markers, also should be considered
but is beyond the scope of our study (21).
Figure 1—Proportion of participants at high risk of developing type 2 diabetes according to each
score, by sex. C and CB are only speciﬁed in the case of various equations provided by the authors.
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The two scoring systems that did not
include age (i.e., Wilson and Balkau) gave
the lowest prevalence rates of subjects
at risk for type 2 diabetes, whereas the
Grifﬁn score, which includes a linear re-
lationship with age (5), provided the
greatest prevalence. It is interesting to
note that the scoring systems using age-
groups instead of age (3,8,9) provided in-
termediate prevalence rates. Considering
how easy it is to collect age and the in-
creasing prevalence of type 2 diabetes
with age (18), we can postulate that this
variable should be included in any risk-
scoring system. Another possible ex-
planation for the low prevalence rates of
participants at risk using theWilson score
is the fact that it includes a low HDL cho-
lesterol level, whose prevalence was
36.9% in the original study. However, in
the CoLaus study (14), the prevalence of
low HDL cholesterol was only 2.8%,
which might lead to spurious results.
Overall, these ﬁndings further stress the
importance of not only including certain
variables but also their relative weighting
and even the way they are coded to com-
pute the risk of developing type 2 dia-
betes.
Only two scoring systems (Wilson
and Kahn [CB]) included fasting glucose.
This was somewhat unexpected because
fasting glucose has a strong predictive
value for diabetes (22). Indeed, in the
study from Balkau et al. (6), fasting glu-
cose was considered to be the best predic-
tor, but no scoring system that included
fasting glucose was provided, possibly be-
cause of the fact that the objective was to
derive a clinically based scoring system.
Most values for each variable included
in the scoring systems were derived from
logistic or Cox regression coefﬁcients.
Still, it should be noticed that some scor-
ing systems (i.e., Swiss Diabetes Associa-
tion) include variables (i.e., familial
history) for which the scores were not
based upon statistical analysis but on an
“educated” proposal by the authors (7).
As a subject might shift from a low-risk
to a high-risk category by one single scor-
ing unit, care should be taken when such
non–evidence-based scores are applied.
Furthermore, the FINDRISC score has
been used (and in some cases modiﬁed)
by others (8,9) without any complemen-
tary statistical analysis or validation; there-
fore, the results obtained by these
modiﬁed, nonvalidated scores might be
questionable. Finally, many scoring sys-
tems did not take into account the non-
linear association between some variables
(i.e., alcohol consumption) and diabetes
risk; the reason might be that introducing
nonlinearity complicates the scoring sys-
tem, but no precise rationale could be ob-
tained from the literature.
The prevalence rates of participants at
risk for developing type 2 diabetes varied
almost 13-fold according to the scoring
system used, leading to considerable dif-
ferences in the number of subjects ame-
nable to prevention measures in the
corresponding Swiss population. This
great variability can be partly explained
by the differences between the scoring
systems. First, the variables used and their
corresponding coefﬁcients varied consid-
erably. Second, the thresholds used to
deﬁne subjects at high risk also varied
(30–46%), as shown in Table 1. Third,
and as stated previously, the scoring sys-
tems were developed and validated in a
given population, and applying them to a
different population can lead to inconsis-
tent results, as it has been underlined in a
previous German study (16). Overall, our
results suggest that the indiscriminate use
of a nonvalidated scoring system might
lead to considerable differences in the
number of subjects to prevent, with a
likely under- or overuse of the limited
available preventive resources.
The agreement between the different
scoring systems was disappointing. In-
deed, we initially expected that two scor-
ing systems detecting a low number of
subjects at risk for diabetes would detect
the same patients, but Fig. 2 shows that it
is not the case. Likewise, even two scoring
systems that included broadly the same
Table 1—Number of participants in the Swiss population at high risk of developing type 2 diabetes according to each score,
by sex and age-group
Sex and
age-group
Total Swiss
population Wilson Balkau (C) Kahn (C)
Swiss Diabetes
Association Kahn (CB) Grifﬁn FINDRISC
Men
Age (years)
35–44 620,900 4,964 12,046 36,924 18,462 34,745 35,471 29,116
45–54 529,600 11,275 15,066 44,500 55,775 60,165 80,869 86,506
55–64 441,700 9,281 24,394 84,151 77,181 85,325 145,119 146,256
65–75 304,300 1,360 18,430 47,762 75,055 47,762 157,613 94,240
Total 1,896,500 26,879 69,937 213,338 226,474 227,998 419,072 356,118
Women
Age (years)
35–44 615,900 4,262 8,523 15,647 11,385 10,654 7,854 21,309
45–54 522,500 5,133 11,434 20,022 37,148 23,427 25,714 55,443
55–64 449,100 7,670 19,132 48,363 77,083 46,914 71,330 104,865
65–75 361,700 2,765 13,166 20,802 72,050 25,641 88,014 99,106
Total 1,949,200 19,829 52,256 104,834 197,666 106,636 192,912 280,722
Total 3,845,700 46,708 122,192 318,172 424,140 334,634 611,984 636,841
C and CB are only speciﬁed in the case of various equations provided by the authors.
Figure 2—Number of patients at high risk of
developing type 2 diabetes according to three
scores.
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variables (i.e., Balkau andKahn [C]) failed
to detect the same participants. Hence,
our results indicate that different scoring
systems detect different subjects at risk for
developing type 2 diabetes and thus are not
interchangeable. Adequate validation of
these scoring systems using prospective
data is therefore necessary to select the
best system applicable to the population
under study. The ongoing follow-up of
theCoLaus cohortwill allow this validation.
Our study has several limitations.
First, the predicting ability of the tested
scores could not be achieved in the
current study. Thus, it is unclear which
of them will be the most accurate. The
ongoing follow-up of the CoLaus cohort
will enable such a comparison. Second,
the prevalence rates according to Swiss
Diabetes Association and FINDRISC may
be over- or underestimated as a result
of our lack of dietary data and second-
degree familial history. Of interest, sensi-
tivity analyses showed that decreasing
the threshold of these scores by two and
three points led to a 50% increase in the
number of subjects at risk for developing
type 2 diabetes (Supplementary Table 6).
These ﬁndings suggest that minor changes
in the scoring system can lead to consider-
able changes in the number of subjects at
risk for developing type 2 diabetes and that
any risk-scoring system should be ade-
quately validated before being applied
in a given population. Third, although the
participation rate was similar to other epi-
demiological studies (23), it was rather low
(41%), which might limit the generaliza-
tion of ﬁndings. Indeed, the CoLaus study
may not be representative of the Swiss pop-
ulation, but seeing the great variability in
the number of high-risk patients, this mis-
take may not be of great relevance. In ad-
dition, there was no sex or ZIP code
distribution difference between the source
population, the random sample, and the
CoLaus participants. On the other hand,
the CoLaus sample had more women and
was slightly younger than the correspond-
ing Swiss population aged 35–75 years
(Supplementary Table 7). Hence, it can be
argued that although the CoLaus sample is
not fully representative of the Swiss popu-
lation, the differences in population struc-
ture are relatively small. Likewise, our
population was at relatively low risk for di-
abetes, and it is unknown how this might
inﬂuence the performance of some of the
risk scores if applied in other populations
or ethnic groups. Still, most equations we
used have been developed in European
countries and should thus be generalizable
to the European population. On the other
hand, it has been shown that risk scores
developed in the same country lead to dif-
ferent results (10). Thus and again, a pre-
cise validation within a given of any risk
score should be conducted before its appli-
cation in clinical or public health practice.
Fourth, diabetic subjects were excluded on
the basis of fasting but not on 2-h plasma
glucose; hence, diabetic subjects by 2-h
glucose (but not by fasting glucose) were
retained in the analysis. Nevertheless, be-
cause the number of subjects with type 2
diabetes (by 2-h glucose) is ﬁxed, our re-
sults still indicate that the number of sub-
jects at risk for developing type 2 diabetes
varies considerably according to the risk
score used. Finally, this article only in-
cluded leisure-time physical activity, and
occupational physical activity was not con-
sidered. Hence, it is possible that the risk of
developing type 2 diabetes might be over-
estimated when using the equations that
include physical activity.
In summary, our results indicate that
the prevalence of participants at risk for
developing type 2 diabetes varies consid-
erably according to the scoring system
used. To adequately prevent type 2 di-
abetes, risk-scoring systems should be
validated for each population considered.
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